DGAP-News

Kizoo Portfolio Company Underdog Closes $10M Financing Round - Seite 2

As part of Michael Greve's Forever Healthy Group, Kizoo directly supports the creation of startups turning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elastrin Therapeutics, and others.

Forever Healthy's other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world's cutting-edge medical knowledge, funding research projects on the root causes of aging and hosting the annual Undoing Aging Conference.

Further information, please visit: www.kizoo.com and www.forever-healthy.org.

About Underdog

Underdog Pharmaceuticals, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.underdogpharma.com.

Media Contact for Kizoo:

Frank Schueler
Managing Director
Kizoo Technology Capital
[e-mail]

Media Contact for Underdog:
Mike Kope
Co-CEO
Underdog Pharmaceuticals Inc
[e-mail]

---

23.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language:	English
Company:	KIZOO Technology Capital GmbH
	Amalienbadstraße 41
	76227 Karlsruhe
	Germany
Phone:	[phone]
E-mail:	[e-mail]
Internet:	www.kizoo.com
EQS News ID:	1235445